Education
About Us
Working with TipRanks
Follow Us
Astellas Pharma (JP:4503)
:4503
Total Valuation
Astellas Pharma has a market cap or net worth of ¥3.80T. The enterprise value is ¥3.33T.
Market Cap¥3.80T
Enterprise Value¥3.33T
Share Statistics
Astellas Pharma has 1,809,663,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,809,663,100
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Astellas Pharma’s return on equity (ROE) is 0.03 and return on invested capital (ROIC) is 16.27%.
Return on Equity (ROE)0.03
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)16.27%
Return on Capital Employed (ROCE)0.11
Revenue Per Employee129.61M
Profits Per Employee3.44M
Employee Count14,754
Asset Turnover0.57
Inventory Turnover1.63
Valuation Ratios
The current PE Ratio of Astellas Pharma is 30.3. Astellas Pharma’s PEG ratio is 0.26.
PE Ratio30.3
PS Ratio1.35
PB Ratio1.71
Price to Fair Value1.71
Price to FCF15.73
Price to Operating Cash Flow9.21
PEG Ratio0.26
Income Statement
In the last 12 months, Astellas Pharma had revenue of 1.91T and earned 50.75B in profits. Earnings per share was 28.35.
Revenue1.91T
Gross Profit1.43T
Operating Income255.67B
Pretax Income31.50B
Net Income50.75B
EBITDA248.30B
Earnings Per Share (EPS)28.35
Cash Flow
In the last 12 months, operating cash flow was 403.20B and capital expenditures -33.65B, giving a free cash flow of 369.56B billion.
Operating Cash Flow403.20B
Free Cash Flow369.56B
Free Cash Flow per Share204.21
Dividends & Yields
Astellas Pharma pays an annual dividend of ¥39, resulting in a dividend yield of 3.6%
Dividend Per Share¥39
Dividend Yield3.6%
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.47
52-Week Price Change46.26%
50-Day Moving Average1.83K
200-Day Moving Average1.54K
Relative Strength Index (RSI)78.15
Average Volume (3m)8.55M
Important Dates
Astellas Pharma upcoming earnings date is Feb 9, 2026, TBA (Confirmed).
Last Earnings DateOct 30, 2025
Next Earnings DateFeb 9, 2026
Ex-Dividend Date―
Financial Position
Astellas Pharma as a current ratio of 1.13, with Debt / Equity ratio of 45.93%
Current Ratio1.13
Quick Ratio0.85
Debt to Market Cap0.32
Net Debt to EBITDA2.59
Interest Coverage Ratio14.46
Taxes
In the past 12 months, Astellas Pharma has paid -19.51B in taxes.
Income Tax-19.51B
Effective Tax Rate-0.62
Enterprise Valuation
Astellas Pharma EV to EBITDA ratio is 13.02, with an EV/FCF ratio of 19.64.
EV to Sales1.69
EV to EBITDA13.02
EV to Free Cash Flow19.64
EV to Operating Cash Flow16.03
Balance Sheet
Astellas Pharma has ¥287.05B in cash and marketable securities with ¥740.54B in debt, giving a net cash position of -¥453.49B billion.
Cash & Marketable Securities¥287.05B
Total Debt¥740.54B
Net Cash-¥453.49B
Net Cash Per Share-¥250.59
Tangible Book Value Per Share-¥14.34
Margins
Gross margin is 78.02%, with operating margin of 13.37%, and net profit margin of 2.65%.
Gross Margin78.02%
Operating Margin13.37%
Pretax Margin1.65%
Net Profit Margin2.65%
EBITDA Margin12.98%
EBIT Margin2.57%
Analyst Forecast
The average price target for Astellas Pharma is ¥1,924.63, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target¥1,924.63
Price Target Upside-2.03% Downside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast13.24%
EPS Growth Forecast127.88%